Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03415854 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
A Phase 2 study, sponsored by HonorHealth Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT03415854 is a Phase 2 study that has completed, run by HonorHealth Research Institute. The registered enrollment target is 34 participants.
The verdict
NCT03415854, a Phase 2 study, has completed, sponsored by HonorHealth Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.
Interventions
- DRUG Paricalcitol (Zemplar)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2023-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03415854
The ClinicalTrials.gov registry entry for NCT03415854 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HonorHealth Research Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paricalcitol (Zemplar) is the first listed.
NCT03415854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03415854 about?
NCT03415854 is a clinical study titled "Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)". The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.
What is the current status of trial NCT03415854?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2018-01-31. Estimated completion is 2023-12-11.
What interventions are being tested in trial NCT03415854?
The interventions under investigation include: Paricalcitol (Zemplar) (DRUG).
Who is sponsoring clinical trial NCT03415854?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.